Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 21;28(10):e202104112.
doi: 10.1002/chem.202104112. Epub 2022 Jan 31.

Synthesis of Polyoxygenated Tropolones and their Antiviral Activity against Hepatitis B Virus and Herpes Simplex Virus-1

Affiliations

Synthesis of Polyoxygenated Tropolones and their Antiviral Activity against Hepatitis B Virus and Herpes Simplex Virus-1

Daniel V Schiavone et al. Chemistry. .

Abstract

Polyoxygenated tropolones possess a broad range of biological activity, and as a result are promising lead structures or fragments for drug development. However, structure-function studies and subsequent optimization have been challenging, in part due to the limited number of readily available tropolones and the obstacles to their synthesis. Oxidopyrylium [5+2] cycloaddition can effectively generate a diverse array of seven-membered ring carbocycles, and as a result can provide a highly general strategy for tropolone synthesis. Here, we describe the use of 3-hydroxy-4-pyrone-based oxidopyrylium cycloaddition chemistry in the synthesis of functionalized 3,7-dimethoxytropolones, 3,7-dihydroxytropolones, and isomeric 3-hydroxy-7-methoxytropolones through complementary benzyl alcohol-incorporating procedures. The antiviral activity of these molecules against herpes simplex virus-1 and hepatitis B virus is also described, highlighting the value of this approach and providing new structure-function insights relevant to their antiviral activity.

Keywords: hepatitis B antivirals; herpes simplex virus antivirals; oxidopyrylium cycloaddition; structure-function analysis; tropolones.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

LAM, JET, and RPM are inventors on patents describing the antiviral activity of tropolones against herpes simplex virus-1 and −2 and hepatitis B virus.

Figures

Figure 1.
Figure 1.
Examples of synthetic, highly oxygenated tropolones and associated biological activity. HIV = human immunodeficiency virus. IMPase = inositol monophosphatase. Crypto = Cryptococcus neoformans.
Figure 2.
Figure 2.
Additional compounds with high relevance to structure-function analysis included in Tables 1 and 2.
Scheme 1.
Scheme 1.
Synthesis and Biological Activity of Highly Oxygenated Tropolones. (A) Overview of oxidopyrylium cycloaddition approach to oxygenated tropolones. (B) Binding mode of α–hydoxytropolones (αHTs) to dinuclear metalloenzymes. (C) Examples of molecules synthesized through this strategy with associated antiviral activity against hepatitis B virus (HBV) and Herpes Simplex Virus-1 (HSV-1)
Scheme 2.
Scheme 2.
Synthesis of 3,7-dimethoxytropolones 2a-d and 3,7-dihydroxytropolones 4a-d. Previously reported reaction with yields are denoted as [a] and [b], for reference and , respectively. [c] Two steps from 6 without isolation of 7a-d.
Scheme 3.
Scheme 3.
Synthesis of 3-hydroxy-7-methoxytropolones 10a-d.
Scheme 4.
Scheme 4.
Synthesis of 3-hydroxy-7-methoxytropolones 10e-f. aSynthesis of 2g and 4g was described in ref. .
Scheme 5.
Scheme 5.
Synthesis of 3-hydroxy-7-methoxytropolones (A) through benzyl alcohol incorporation (14a and 14d), and (B) through room temperature BCl3 reaction for 8b.

Similar articles

Cited by

References

    1. For select examples, see: Iwatsuki M, Takada S, Mori M, Ishiyama A, Namatame M, Otoguro K, Nishihara-Tsukashima A, Nonaka K, Masuma R, Otoguro O, Shiomi K, Omura S, J. Antibiot 2011, 64, 183–188.; - PubMed
    2. Sugawara K, Ohbayashi M, Shimizu K, Hatori M, Kamei H, Konishi M, Oki T, Kawaguchi H, J. Antibiot 1988, 41, 862–868.; - PubMed
    3. Credille CV, Dick BL, Morrison CN, Stokes RW, Adamek RN, Wu NC, Wilson IA, Cohen SM, S. M. J. Med. Chem 2018, 61, 10206–10217.; - PMC - PubMed
    4. For review, see: Meck C, D'Erasmo MP, Hirsch DR, Murelli RP, Med. Chem. Commun 2014, 5, 842–852. - PMC - PubMed
    1. For some examples of synthetic chemistry-driven SAR, see: Piettre SR, Andre C, Chanal MC, Ducep JB, Lesur B, Piriou F, Raboisson P, Rondeau JM, Schelcher C, Zimmermann P, Ganzhorn AJ, J. Med. Chem 1997, 40, 4208–4221.; - PubMed
    2. Didierjean J, Isel C, Querre F, Mouscadet J-F, Aubertin A-M, Valnot J-Y, Piettre SR, Marquet R, Antimicrob. Agents Chemother 2005, 49, 4884–4894.; - PMC - PubMed
    3. Chung S, Himmel D, Jiang J-K, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SFJ, J. Med. Chem 2011, 54, 4462–4473.; - PMC - PubMed
    4. Sennari G, Saito R, Hirose T, Iwatsuki M, Ishayama A, Hokari R, Otoguro K, Omura S, Sunazuka T, Sci. Rep 2017, 7, 7259.; - PMC - PubMed
    5. Agyemang NB, Kukla CR, Edwards TC, Li Q, Langen MK, Schaal A, Franson AD, Gazquez Casals A, Donald KA, Yu AJ, Donlin MJ, Morrison LA, Tavis JE, Murelli RP, RSC Advances, 2019, 9, 34227–34234. - PMC - PubMed
    6. Saito R, Sennari G, Nakajima A, Kiminishi A, Iwatsuki M, Ishiyawa A, Hokari R, Hirose T, Sunazuka T, Chem. Pharm. Bull 2021, 69, 564–572. - PubMed
    1. Meck C, Mohd N, Murelli RP, Org. Lett 2012, 14, 5988–5991.; - PMC - PubMed
    2. Berkowitz AJ, Abdelmessih RG, Murelli RP, Tetrahedron Lett. 2018, 59, 3026–3028. - PMC - PubMed
    1. Murelli RP, D'Erasmo MP, Hirsch DR, Meck C, Masaoka T, Wilson JA, Zhang B, Pal RK, Gallicchio E, Beutler JA, Le Grice SFJ, Med. Chem. Commun 2016, 9, 1783–1788.; - PMC - PubMed
    2. Zhang B, D'Erasmo MP, Murelli RP, Gallicchio E, ACS Omega, 2016, 1, 435–447.; - PMC - PubMed
    3. For seminal studies, see Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, Crouch RJ, McMahon JB, Beutler JA, Le Grice SFJ, Nucleic Acids Res. 2005, 33, 1249–1256. - PMC - PubMed
    1. Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SFJ, Thomas CJ, Jiang J-K, Meck C, Hirsch DR, R. D; D'Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE, Antimicrob. Agents Chemother 2015, 59, 1070–1079.; - PMC - PubMed
    2. Lomonosova E, Daw J, J.; Garimallaprabhakaran AK, Agyemang NB Ashani Y, Murelli RP, Tavis JE, Antiviral Res. 2017, 144, 164–172.; - PMC - PubMed
    3. Long KR, Lomonosova E, Li W, Ponzar NL, Villa JA, Touchette E, Rapp S, Liley RM, Murelli RP, Grigoryan A, Buller RM, Wilson L, Bial J, Sagartz JE, Tavis JE, Antiviral Res. 2018, 149, 41–47.; - PMC - PubMed
    4. For seminal studies, see Hu Y, Cheng X, Cao F, Huang A, Tavis JE, Antiviral Res. 2013, 99, 221–229. - PubMed

LinkOut - more resources